AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19080533
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with salmeterol/fluticasone (50/250 microg) twice daily and tiotropium 18 microg once daily (n = 33, M/F: 23/10)
Trial: 19080533
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with salmeterol/fluticasone and tiotropium
Trial: 19080533
Drug: Salmeterol/fluticasone (50/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone (50/250 microg) twice daily (n = 32, M/F: 24/8)
Trial: 19080533
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 microg once daily (n = 32, M/F: 23/9)
Trial: 12118027
Drug: PVI 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PVI 5-FU (300 mg/m²/d for a maximum of 24 weeks)
Trial: 12118027
Drug: PVI 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PVI 5-FU plus MMC (7 mg/m² every 6 weeks for four courses)
Trial: 2303688
Drug: Emergency sclerotherapy
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency sclerotherapy with larger volumes of sclerosant (mean of 26 ml)
Trial: 7374618
Drug: oxygen-multistep-therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxygen-multistep-therapy
Trial: 27919633
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose inactivated influenza vaccine (HD IIV)
Trial: 27919633
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose inactivated influenza vaccine (SD IIV)
Trial: 26391700
Drug: Cyproterone acetate/ethinyloestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate/ethinyloestradiol with metformin
Trial: 26391700
Drug: Cyproterone acetate/ethinyloestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate/ethinyloestradiol without metformin
Trial: 26391700
Drug: PCOS without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCOS without insulin resistance (IR)
Trial: 11881062
Drug: Lisinopril (ACE-I)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (ACE-I)
Trial: 11881062
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Candesartan cilexetil and Lisinopril)
Trial: 3043355
Drug: roxithromycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin (150 mg bd)
Trial: 3043354
Drug: erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: erythromycin ethylsuccinate (1 g bd)
Trial: 31544377
Drug: Fresh leonurus
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh leonurus japonicus capsule, 0.8 g, 3 times a day for 7 days, for 3 courses until embryo transfer.
Trial: 23648075
Drug: Intravenous supply
RxNorm normalized name: SUPPLY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous supply of omega-3 PUFAs (EPA and DHA)
Trial: 21614496
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg) twice daily for 3 months followed by CC/HMG/HCG for 3 months
Trial: 21614496
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 3 months followed by CC/HMG/HCG for 3 months
Trial: 18221256
Drug: Daclizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1 mg/kg infusion 2 hours before transplantation and then every 14 days for four more doses)
Trial: 18221256
Drug: Tacrolimus-based therapy
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus-based therapy without daclizumab (historical control group)
Trial: 17722304
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% vitamin C derivative (VC-PMG)
Trial: 17722304
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% vitamin E
Trial: 12923149
Drug: Hysteroscopic adhesiolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysteroscopic adhesiolysis plus intrauterine application of ACP gel (10 ml)
Trial: 9123741
Drug: Neoadjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant androgen suppression prior to radiation therapy
Trial: 28988549
Drug: TAU (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (treatment as usual) plus low‐intensity CBT‐Music (treatment)
Trial: 18411039
Drug: Cochrane reviews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochrane reviews (drug interventions)
Trial: 18411039
Drug: DARE reviews
RxNorm normalized name: Darexaban
DrugBank: Darexaban (DB12289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DARE reviews (drug interventions)
Trial: 12913326
Drug: Mixture containing
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture containing acetyl‐L‐carnitine (ALC), polyunsaturated fatty acids (PUFAs), coenzyme Q10 (CoQ10) and vitamin E
Trial: 10873918
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (adding a selective serotonin reuptake inhibitor)
Trial: 9199588
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B Ortho toothbrushes
Trial: 9199588
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B Plus 35 toothbrushes
Trial: 1549027
Drug: Propranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10 mg, oral dose)
Trial: 4077364
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg metoprolol (i.v.)
Trial: 4077364
Drug: 0.30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg/kg metoprolol (i.v.)
Trial: 4077364
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with slow-release metoprolol (1 X 200 mg/day for 4 weeks)
Trial: 30376962
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (10 mg/kg)
Trial: 27153745
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg E4/DRSP
Trial: 27153745
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg E4/LNG
Trial: 26891216
Drug: Black raspberry
RxNorm normalized name: BLACK RASPBERRY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black raspberry (750 mg/day)
Trial: 22464728
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual including occupational therapy (TAU)
Trial: 22166634
Drug: Tailored loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored loading dosage of clopidogrel
Trial: 22166634
Drug: Rational loading
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational loading dosage of clopidogrel
Trial: 11286312
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment with dalteparin for 3 months after initial treatment
Trial: 25359642
Drug: Invasive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive therapy
Trial: 9412548
Drug: Albuterol 400
RxNorm normalized name: albuterol 400 MCG/ACTUAT Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 400 micrograms
Trial: 1829368
Drug: Bendrofluazide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide (5 mg once daily)
Trial: 30317262
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of 10mg of 0.5% hyperbaric bupivacaine (Group A)
Trial: 30317262
Drug: Height and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Height and weight-adjusted dose of 0.5% hyperbaric bupivacaine (Group B)
Trial: 30768407
Drug: Sertraline for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline for 12 weeks
Trial: 18837604
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (group and individual)
Trial: 14613676
Drug: 5-HT(2) antagonists
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT(2) antagonists (clozapine or olanzapine)
Trial: 1466849
Drug: Dapsone (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone (100mg orally twice weekly)
Trial: 1466849
Drug: Pentamidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentamidine (400 mg nebulized monthly)
Trial: 31535100
Drug: 11-mm-long implants
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11-mm-long implants combined with maxillary sinus floor elevation
Trial: 31535100
Drug: 6-mm-long implants
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mm-long implants without any grafting
Trial: 28522762
Drug: Postmeal exercise
RxNorm normalized name: OATMEAL
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postmeal exercise with metformin
Trial: 28522762
Drug: Metformin/sedentary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/sedentary
Trial: 28522762
Drug: Metformin/exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/exercise
Trial: 18675519
Drug: Imipramine (1mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (1mg/kg daily, max 100mg)
Trial: 18675519
Drug: Fluoxetine (5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (5mg for >40kg, 10mg for 40-60kg, 20mg for >60kg)
Trial: 15970897
Drug: Contraceptive patch
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive patch (ethinyl estradiol [EE] 20 microg/d and norelgestromin 150 microg/d)
Trial: 15970897
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (EE 35 mug and norgestimate 250 microg)
Trial: 12878917
Drug: Naltrexone and
RxNorm normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone and acamprosate (16 weeks of active treatment)
Trial: 12878917
Drug: No-pill psychotherapy-alone
RxNorm normalized name: No Doz Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-pill psychotherapy-alone condition
Trial: 10474019
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day ipriflavone
Trial: 10474019
Drug: 0.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/day calcium lactate
Trial: 8695365
Drug: Gemcitabine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine administered as a 24 h infusion at a maximum tolerated dose (MTD) of 180 mg m‐2 on days 0, 7, and 14, repeated every 28 days.
Trial: 8695365
Drug: Gemcitabine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine administered as a 24 h infusion at various dose levels (10, 20, 40, 80, 120, 180, and 210 mg m‐2).
Trial: 8695365
Drug: Maximum tolerated
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum tolerated dose of gemcitabine.
Trial: 1878329
Drug: 2% solution
RxNorm normalized name: Lidomar 2% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% solution of mineralizing agent and 0.2% NaF solution
Trial: 1878329
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and 0.2% NaF solutions
Trial: 11216430
Drug: Minilaparoscopy (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minilaparoscopy (ML)
Trial: 19789191
Drug: Intravenous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous low dose dexamethasone (4 mg initial dose, followed by 2 mg every 8 hours for 24 hours)
Trial: 15036491
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) treatment for 12 or 14 days with combinations of 1 mg or 2 mg E2V and 2.5 mg or 5 mg MPA.
Trial: 11485531
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (122 patients)
Trial: 8047805
Drug: Pivmecillinam, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam, 50 mg/kg.day for 5 days
Trial: 8047805
Drug: Nalidixic acid,
RxNorm normalized name: Nalidixic Acid, 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalidixic acid, 60 mg/kg.day for 5 days
Trial: 30106530
Drug: Two-step 0.454%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-step 0.454% SnF₂ dentifrice and 3% H₂O₂ gel sequence
Trial: 28942806
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care (low intensity, standard CBT, individually tailored treatment)
Trial: 28942806
Drug: Single, empirically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, empirically validated cognitive-behavioral therapy (CBT) program
Trial: 23589527
Drug: Ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion at 0.2 nmol kg(‐1) h(‐1)
Trial: 23589527
Drug: Ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion at 0.6 nmol kg(‐1) h(‐1)
Trial: 18088076
Drug: Open donepezil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open donepezil treatment
Trial: 8740617
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no advanced preparation
Trial: 1907422
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous nitroglycerin (33 micrograms/min)
Trial: 1907422
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous nitroglycerin (133 micrograms/min)
Trial: 30415593
Drug: Ocrelizumab 600
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 600 mg every 24 weeks for ⩾120 weeks
Trial: 30415593
Drug: Ocrelizumab 600
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 600 mg
Trial: 27835715
Drug: Adjunctive ziprasidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive ziprasidone (escitalopram + ziprasidone, n = 71)
Trial: 25727243
Drug: Forward leaning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forward leaning body posture with inhalation of 200 μgr salbutamol
Trial: 25727243
Drug: Standard body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard body posture with inhalation of 200 μgr salbutamol
Trial: 14617545
Drug: Right ventricular
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right ventricular pacing (RVP) patients with drug resistant heart failure (group B)
Trial: 11198726
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg once daily for 7 days)
Trial: 9157756
Drug: Tizanidine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine (12 mg/day)
Trial: 9157756
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 mg/day)
Trial: 8228368
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) (160/800 mg)
Trial: 30753384
Drug: Nitazoxanide (NTZ)
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (NTZ) 600 mg twice daily for age ≥12 years; 200 mg for age 4-11 years; 100 mg for age 1-3 years for 5 days
Trial: 27477534
Drug: 1 per
RxNorm normalized name: ALOE VESTA 2-N-1 PERINEAL CLEANSER SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 per cent clotrimazole solution
Trial: 18412024
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Loprax) 400 mg cefixime
Trial: 18412024
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation 400 mg cefixime
Trial: 8624641
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 15 mg weekly, increased to 25 mg for poor responders
Trial: 2869996
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin regimen designed to maintain near‐normal glycemic levels
Trial: 2869996
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with up to two insulin injections daily
Trial: 30536595
Drug: sacubitril/valsartan 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan 400 mg
Trial: 17060062
Drug: olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan 20 mg
Trial: 30180960
Drug: Combination simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination simvastatin (40 mg)/ezetimibe (10 mg)
Trial: 30180960
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg) alone
Trial: 24021896
Drug: Bromfenac ophthalmic
RxNorm normalized name: bromfenac ophthalmic
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac ophthalmic solution 0.07%
Trial: 16060219
Drug: NaFeEDTA-fortified soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaFeEDTA-fortified soy sauce (29.6 mg Fe/100 ml)
Trial: 12803733
Drug: Rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg/day
Trial: 12398960
Drug: Rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg/day plus atorvastatin 10 mg/day
Trial: 12398960
Drug: Rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg/day plus atorvastatin 20 mg/day
Trial: 2538499
Drug: Nedocromil sodium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium, 4 mg
Trial: 4616804
Drug: Oxolinic acid
RxNorm normalized name: oxolinic acid
DrugBank: Oxolinic acid (DB13627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxolinic acid (750 mg twice-daily for 14 days)
Trial: 4616804
Drug: Ampicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (500 mg 3-times daily for 14 days)
Trial: 12611485
Drug: G-CSF 5
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF 5 microg/kg per day
Trial: 15848703
Drug: ATG-Fresenius (4-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG-Fresenius (4-6 mg/kg body weight)
Trial: 15848703
Drug: Thymoglobulin (1.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin (1.5-2.5 mg/kg body weight)
Trial: 11932960
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole with 400 mg of didanosine (encapsulated, enteric-coated bead formulation)
Trial: 11932960
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg fluconazole with 400 mg of didanosine (encapsulated, enteric-coated bead formulation)
Trial: 2545979
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (CAV)
Trial: 2545979
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy using three different drug combinations
Trial: 795456
Drug: Propranolol (Inderal)
RxNorm normalized name: propranolol Extended Release Oral Capsule [Inderal]
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (Inderal) 20 mg
Trial: 795456
Drug: Propranolol (Inderal)
RxNorm normalized name: propranolol Extended Release Oral Capsule [Inderal]
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (Inderal) 40 mg
Trial: 795456
Drug: Propranolol (Inderal)
RxNorm normalized name: propranolol Extended Release Oral Capsule [Inderal]
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (Inderal) 80 mg